Stock OBSEF OBSEVA SA
Add to a list
To use this feature you must be a member
Log inSign up

Company ObsEva SA OTC Markets

Equities

OBSEF

CH1260041939

Biotechnology & Medical Research

Delayed OTC Markets
Other stock markets
 12:54:02 2024-04-22 pm EDT 		5-day change 1st Jan Change
0.005 USD +150.00% Intraday chart for ObsEva SA +1,150.00% -85.71%
Apr. 03 ObsEva to Delist from the SIX Swiss Exchange MT
Mar. 20 ObsEva SA Announces to Wind-Down the Operations CI

Business Summary

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis and uterine fibroids; Nolasiban (OBE001), an oral oxytocin receptor antagonist, with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART), and OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor.

Number of employees: 15

Sales per Business

CHF in Million2021Weight2022Weight Delta
Women's Reproductive, Health and Pregnancy Therapeutics
100.0 %
0 nan % 19 100.0 % -

Sales per region

CHF in Million2021Weight2022Weight Delta
Switzerland
100.0 %
0 nan % 19 100.0 % -

Managers

Managers TitleAgeSince
Fabien de Ladonchamps CEO
 Chief Executive Officer 45 23-04-30
Ernest Loumaye FOU
 Founder 71 12-11-13
Katja Buhrer PRN
 Corporate Officer/Principal - 22-01-31

Members of the board

Members of the board TitleAgeSince
Ernest Loumaye FOU
 Founder 71 12-11-13
Luigi Marro BRD
 Director/Board Member - 23-06-28

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 146,919,237 103,079,787 ( 70.16 %) 29,741,950 ( 20.24 %) 70.16 %

Shareholders

NameEquities%Valuation
OBSEVA SA
22.97 %
33,741,950 22.97 % 486 896 $
Ernest Loumaye
6.806 %
10,000,000 6.806 % 144 300 $
JGB Capital Management LP
1.425 %
2,093,952 1.425 % 30 216 $
Annette Clancy
0.0664 %
97,500 0.0664 % 1 407 $
DWS CH AG
0.0209 %
30,689 0.0209 % 443 $
CATAM Asset Management AG
0.006806 %
10,000 0.006806 % 144 $
State Street Global Advisors France SA
0.003411 %
5,011 0.003411 % 72 $
LLB Asset Management AG
0.002659 %
3,907 0.002659 % 56 $
Ed Mathers Mathers
0.000000 %
0 0.000000 % - $
Brian O'Callaghan
0.000000 %
0 0.000000 % - $

Holdings

NameEquities%Valuation
OBSEVA SA
22.97%
 33,741,950 22.97% 486,896 $

Company contact information

ObsEva SA

Chemin des Aulx, 12 Plan-les-Ouates

1228, Geneva

+41 22 552 38 40

http://www.obseva.com
address ObsEva SA(OBSEF)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.49% 96.73B
ARGENX SE Stock argenx SE
-1.86% 21.31B
BIONTECH SE Stock BioNTech SE
-16.61% 21.21B
GENMAB A/S Stock Genmab A/S
-5.80% 18.79B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.14% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-27.40% 13.68B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+1.44% 13.44B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+21.29% 10.98B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-21.79% 8.56B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. OBSN Stock
  4. OBSEF Stock
  5. Company ObsEva SA